26Apr/13

Neue Therapien, Risikofaktoren und andere Neuigkeiten aus der Multiple … – DMSG Multiple Sklerose Nachrichten

Neue Therapien, Risikofaktoren und andere Neuigkeiten aus der Multiple
DMSG Multiple Sklerose Nachrichten
Eine einjährige Verlängerung einer Phase II Studie mit Daclizumab-HYP, einer veränderten Form des Daclizumab, zeigte dass monatliche Injektionen unter die Haut auch weiterhin die Schubhäufigkeit, die im MRT sichtbare Krankheitsaktivität und die

26Apr/13

Risks of living organ donation not 'sinking in,' researcher says – nwitimes.com


CTV News

Risks of living organ donation not ‘sinking in,’ researcher says
nwitimes.com
Risks of living organ donation not ‘sinking in,’ researcher says. » 2013-04-26T00:00:00Z 2013-04-26T11:04:07Z Risks of living organ donation not ‘sinking in,’ researcher saysMegan Carlson nwitimes.com. 11 hours ago • Megan Carlson. Living organ donors
Plan ahead to save lives: Be an organ donorDavidsonNews.net (blog)
Our View: Sign up to be an organ donor and save a lifeRockford Register Star
Beth Piraino is the president of the National Kidney Foundation.New York Times
AberdeenNews.com –CTV News –vtdigger.org
all 41 news articles »
26Apr/13

AbbVie's Management Discusses Q1 2013 Results – Earnings Call Transcript – Seeking Alpha

AbbVie’s Management Discusses Q1 2013 Results – Earnings Call Transcript
Seeking Alpha
This includes Daclizumab, which is in Phase III development in partnership with Biogen, for relapsing remitting multiple sclerosis. Data from the first of two registrational trials, the select study, were recently published in the Lancet. And results

and more »